NASDAQ:KIN - Kindred Biosciences Price Target & Analyst Ratings

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

7 Wall Street analysts have issued ratings and price targets for Kindred Biosciences in the last 12 months. Their average twelve-month price target is $18.75, suggesting that the stock has a possible upside of 126.72%. The high price target for KIN is $25.00 and the low price target for KIN is $12.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."

Show: Only the Most Recent Rating From Each Brokerage All Ratings For This Stock